Stock OMIC SINGULAR GENOMICS SYSTEMS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
0.375 USD +2.82% Intraday chart for Singular Genomics Systems, Inc. -1.57% -18.50%
May. 15 Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating MT
May. 14 Transcript : Singular Genomics Systems, Inc., Q1 2024 Earnings Call, May 14, 2024

Business Summary

Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.

Number of employees: 255

Sales per Business

USD in Million2022Weight2023Weight Delta
Proprietary Sequencing Solutions
100.0 %
1 100.0 % 3 100.0 % +280.52%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 3 100.0 % +280.52%

Managers

Managers TitleAgeSince
Eli Glezer FOU
 Founder 55 16-05-31
Andrew Spaventa CEO
 Chief Executive Officer 39 16-05-31
Dalen Meeter DFI
 Director of Finance/CFO 46 19-11-30
Matthew Clawson IRC
 Investor Relations Contact - -
Jeff Bullard SAM
 Sales & Marketing - 22-08-01
Vincent Brancaccio HRO
 Human Resources Officer 41 19-08-31
Sam Ropp PRN
 Corporate Officer/Principal - 22-08-01
Jorge Velarde PRN
 Corporate Officer/Principal 57 18-09-30

Members of the board

Members of the board TitleAgeSince
David Barker FOU
 Founder 82 16-08-31
Kim Kamdar BRD
 Director/Board Member 56 17-04-30
Michael Pellini BRD
 Director/Board Member 58 17-03-31
Elaine Mardis BRD
 Director/Board Member 61 22-01-04
Jason Ryan BRD
 Director/Board Member 49 21-03-31
Andrew Spaventa CEO
 Chief Executive Officer 39 16-05-31
Marcia Eisenberg BRD
 Director/Board Member 65 23-08-03

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,092,970 60,424,711 ( 81.55 %) 0 81.55 %

Shareholders

NameEquities%Valuation
Deerfield Management Co. LP
7.271 %
5,386,655 7.271 % 2 M $
Deerfield Management Co. LP (Private Equity)
6.729 %
4,984,871 6.729 % 2 M $
Eli Glezer
6.209 %
4,600,000 6.209 % 2 M $
Legend Capital Co. Ltd.
6.152 %
4,557,662 6.152 % 2 M $
Andrew Spaventa
5.615 %
4,159,895 5.615 % 2 M $
ARCH Venture Partners LLC
5.128 %
3,798,926 5.128 % 2 M $
Domain Associates LLC
5.081 %
3,763,985 5.081 % 2 M $
QVIDTVM Management LLC
3.384 %
2,506,695 3.384 % 1 M $
UBS Group AG (13f Subfiler)
2.982 %
2,209,383 2.982 % 885 963 $
Perceptive Advisors LLC
2.871 %
2,126,893 2.871 % 852 884 $
NameEquities%Valuation
Deerfield Management Co. LP (Private Equity)
100.00 %
2,500 100.00 % 1 003 $

Company contact information

Singular Genomics Systems, Inc.

3010 Science Park Road

92121, San Diego

+

http://www.singulargenomics.com
address Singular Genomics Systems, Inc.(OMIC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Singular Genomics Systems, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.375 USD
Average target price
0.75 USD
Spread / Average Target
+100.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SINGULAR GENOMICS SYSTEMS, INC. Stock Singular Genomics Systems, Inc.
-18.50% 27.78M
MODERNA, INC. Stock Moderna, Inc.
+48.64% 56.65B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.44% 39.44B
LONZA GROUP AG Stock Lonza Group AG
+37.07% 39.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.28% 26.75B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.86B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.40% 19.03B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.64% 12.26B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.96% 12.28B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.04% 12.04B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OMIC Stock
  4. Company Singular Genomics Systems, Inc.